Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck Trial will investigate OBT076 as monotherapy and in sequence with balstilimabCD205, OBT076’s target antigen, is overexpressed in ~ 80 % of ACC tumor biopsy samplesRecurrent or metastatic ACC patients...

Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at World ADC Conference 2023 Engine will combine OBT’s internationally recognised target discovery and ADC development capabilitiesOBT will also present a case study and two abstracts focussing on its recent novel target...

Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards Oxford, UK and San Jose, Calif., 7 March 2023- Oxford BioTherapeutics...